Bartter Syndrome Clinical Trial
— AZOfficial title:
Acetazolamide (AZ) for Management of Refractory Hypokalemia Metabolic Alkalosis in Bartter Syndrome
In this prospective controlled cross over clinical trial, the investigators aim to evaluate the efficacy and safety of acetazolamide for the management of metabolic alkalosis in children with Bartter syndrome. Urine and blood electrolytes will be measured before and after acetazolamide treatment. The primary end point is a change in polyuria, hypokalemia, and metabolic alkalosis.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | December 30, 2019 |
Est. primary completion date | October 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year to 10 Years |
Eligibility |
Inclusion Criteria: - Hypokalemia - metabolic alkalosis - normal blood pressure - random urine chloride >20 milliequivalent per liter (mEq/L) - Elevated serum aldosterone and renin levels Exclusion Criteria: - Hypertension - History of emesis - Prior use of laxatives - Cystic fibrosis ofpancrease |
Country | Name | City | State |
---|---|---|---|
Iran, Islamic Republic of | Fateme Ghane Sharbaf | Mashhad | |
Iran, Islamic Republic of | Semnan University of Medical Sciences | Semnan | |
Iran, Islamic Republic of | Banafshe Dormansh | Tehran | |
Iran, Islamic Republic of | Simin Sadeghi | Zahedan |
Lead Sponsor | Collaborator |
---|---|
Tehran University of Medical Sciences |
Iran, Islamic Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Metabolic alkalosis | Change in serum bicarbonate level | 4 weeks | |
Primary | Urine output | Change in 24-hr urine volume | 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|